PROGRAM
July 11-14, 2020
Beijing
GMT +8

Session 1 (5:30pm-7pm)

Digital health & Biomarkers

  • State of the art of telemedicine trial results – J Cleland / UK
  • Using biomarkers in HF – update 2020 – J Januzzi / USA
  • Managing HF patients in COVID-19 times – Y Zhang / CHI
  • Big data and AI approaches – what is on the horizon?
    V Mahajan / IND
Athens
GMT +3

Session 4 (5:30pm-7pm)

State of the art management of chronic HF

  • RAASi/ARNi, MRAs and beta blockers – F Zannad / FRA
  • SGLT2 inhibitors
    M Packer / USA
  • Vericiguat, the new data
    B Pieske / GER
  • Managing anticoagulation in HF
    G Rosano / ITA

Keynote Lecture (7:00pm-7:25pm)

  • Gold-standard treatment of HFrEF in 2020 – J. McMurray / UK
New York
GMT -4

Session 7 (5:30pm-7pm)

Update on acute HF

  • Management of AHF – State of the art – G Filippatos / GR
  • Post MI acute heart failure
    A Hernandez / USA
  • Inflammatory cardiomyopathy and viral myocarditis
    B Bozkurt / USA
  • Cardiogenic shock
    O Chioncel / ROM

Session 2 (8:30pm-10pm)

Basics in HF: Epidemiology, clinical settings, treatments

  • Treatment algorithm of HFrEF
    J Ezekowitz / CAN
  • HFrEF vs HFmrEF vs HFpEF – similarities and differences
    P Seferovic / SRB
  • Diagnostic approaches in HFpEF – C Lam / SING
  • Treatment approaches in HFpEF – S Solomon / USA

Session 11 (8:30pm-10pm)

Late-breaking Abstracts (part 1)

  • SOBOTA-HF study: HF prevalence in the general population
    M. Lainscak / SVN
  • Data from the Swedish HF Registry : Lower socioeconomic status predicts higher mortality & morbidity … – similarities and differences
    B. Schrage / SWE
  • EMPERIAL trials update
    W, Abraham / USA
  • Data from the EMPA-REG Outcomes trial – S. Anker / GER
  • AMBER trial: results in the pre-specified subgroup with heart failure – P. Rossignol / FR
Getting to the heart of managing heart failure
(Amgen, Cytokinetics, Servier)

Session 8 (8:30pm-10pm)

Update on advanced HF, assist devices and heart transplantation

  • Patient with very poor prognosis and very low EF
    D Ju Choi / Korea
  • Mechanical circulatory support (MCS) – F Bader / UAE
  • Heart transplantation vs destination LVAD
    L Stevenson / USA
  • Organising cardiac surgery and interventional care for HF in Covid times – M Metra / ITA
Beijing
GMT +8

Session 9 (5:30pm-7pm)

Difficult problems in HF

  • The patient with low blood pressure and poor renal function with acute HF
    S Matskeplishvili / RUS
  • Elderly patient with mid-range EF and suspicion of amyloid
    S Zieroth / CAN
  • Causes and management of heart failure in low resource settings – K Sliwa / SA
  • The patient with cancer and cardio-toxic chemotherapy
    A Lyon / UK
Athens
GMT +3

Session 5 (5:30pm-7pm)

Co-morbidities in HF(part 1)

  • Diabetes in HF – J McMurray / UK
  • Atrial Fibrillation – J Atherton / AUS
  • Managing obesity and cachexia – M Abdelhamid / EGY
  • Sleep Apnea – M Boehm / GER
New York
GMT -4

Session 12 (5:30pm-7pm)

DAPA HF one year on: what have you missed?

  • Effect of dapagliflozin on outpatient worsening in patients with HFrEF – J McMurray / UK
  • Benefit of dapagliflozin on first and repeat events in patients with HFrE – P Ponikowski / POL
  • DAPA-HF: effect of dapagliflozin on renal outcomes in HFrEF
    S Solomon / USA
  • Impact of dapagliflozin treatment on KCCQ
    M. Kosiborod / USA
  • Dapagliflozin and diuretic use in patients with HFrEF
    A. Jackson / UK

Session 10 (8:30pm-10pm)

New drugs and devices for HF therapy

  • Omecamtiv Mecarbil for chronic HF
    J Teerlink / USA
  • Devices for functional MR beyond Mitraclip
    S von Bardeleben / GER
  • Devices for baroreflex stimulation – A Coats / AUS
  • More on new drugs and devices on the horizon – S Anker / GER

Session 6 (8:30pm-10pm)

Co-morbidities in HF (part 2)

  • CKD – C Yancy / USA
  • Hyperkalemia – J Butler / USA
  • ID with and without anaemia
    P Ponikowski / POL
  • Exercise and managing frailty – S.Makita / JAP

Session 3 (8:30pm-10pm)

Valvular heart disease in HF

  • State of art for imaging for diagnosis of valvular disease and assessment of risk
    F Pinto / POR
  • Aortic valve disease
    A Abizaid / Brazil
  • Tricuspid disease
    H Sievert / GER
  • Mitral valve disease
    W Abraham / USA
Beijing
GMT +8

Session 7 (5:30pm-7pm)

Update on acute HF

  • Management of AHF – State of the art – G Filippatos / GR
  • Post MI acute heart failure
    A Hernandez / USA
  • Inflammatory cardiomyopathy and viral myocarditis
    B Bozkurt / USA
  • Cardiogenic shock
    O Chioncel / ROM
Athens
GMT +3

Session 1 (5:30pm-7pm)

Digital health & Biomarkers

  • State of the art of telemedicine trial results – J Cleland / UK
  • Using biomarkers in HF – update 2020 – J Januzzi / USA
  • Managing HF patients in COVID-19 times – Y Zhang / CHI
  • Big data and AI approaches – what is on the horizon?
    V Mahajan / IND
New York
GMT -4

Session 4 (5:30pm-7pm)

State of the art management of chronic HF

  • RAASi/ARNi, MRAs and beta blockers – F Zannad / FRA
  • SGLT2 inhibitors
    M Packer / USA
  • Vericiguat, the new data
    B Pieske / GER
  • Managing anticoagulation in HF – G Rosano / ITA

Session 8 (8:30pm-10pm)

Update on advanced HF, assist devices and heart transplantation

  • Patient with very poor prognosis and very low EF – D Ju Choi / Korea
  • Mechanical circulatory support (MCS) – F Bader / UAE
  • Heart transplantation vs destination LVAD – L Stevenson / USA
  • Organising cardiac surgery and interventional care for HF in Covid times – M Metra / ITA

Session 2 (8:30pm-10pm)

Basics in HF: Epidemiology, clinical settings, treatments

  • Treatment algorithm of HFrEF – J Ezekowitz / CAN
  • HFrEF vs HFmrEF vs HFpEF – similarities and differences – P Seferovic / SRB
  • Diagnostic approaches in HFpEF – C Lam / SING
  • Treatment approaches in HFpEF – S Solomon / USA

Session 11 (8:30pm-10pm)

Late-breaking Abstracts (part 1)

  • Left ventricular EF & long-term mortality: Insights from the Ntl. Echocardiography Database of Australia
    S. Stewart / AUS
  • Structural heart disease and preserved ejection fraction: Insights from the Ntl. Echocardiography Database of Australia
    D. Playford / AUS
  • Observations from the RELIEVE-HF roll-in cohort – G. Stone / US
  • A comprehensive individual patient data meta-analysis of the effects of cardiac contractility modulation on functional capacity and HF…
    A. Coats / UK
  • An update on the rEF vs mrEF vs pEF landscape
    L. Lund / SWE
Beijing
GMT +8
Athens
GMT +3
New York
GMT -4

Session 6 (5:30pm-7pm)

Co-morbidities in HF (part 2)

  • CKD – C Yancy / USA
  • Hyperkalemia – J Butler / USA
  • ID with and without anaemia
    P Ponikowski / POL
  • Exercise and managing frailty
    S Makita / JAP

Session 11 (5:30pm-7pm)

Late-breaking abstracts (part 3)

  • Left ventricular EF & long-term mortality: Insights from the Ntl. Echocardiography Database of AUS – S. Stewart / AUS
  • Structural heart disease and preserved ejection fraction: Insights from the Ntl. Echocardiography Database of AUS
    D. Playford / AUS
  • Observations from the RELIEVE-HF roll-in cohort – G. Stone / US
  • A comprehensive individual patient data meta-analysis of the effects of cardiac contractility modulation …
    A. Coats, UK

Session 10 (5:30pm-7pm)

New drugs and devices for HF therapy

  • Omecamtiv Mecarbil for chronic HF – J Teerlink / USA
  • Devices for functional MR beyond Mitraclip
    S von Bardeleben / GER
  • Devices for baroreflex stimulation – A Coats / AUS
  • More on new drugs and devices on the horizon – S Anker / GER

Session 5 (8:30pm-10pm)

Co-morbidities in HF(part 1)

  • Diabetes in HF
    J McMurray / UK
  • Atrial Fibrillation
    J Atherton / AUS
  • Managing obesity and cachexia – M Abdelhamid / EGY
  • Sleep Apnea – M Boehm / GER

Session 3 (8:30pm-10pm)

Valvular heart disease in HF

  • State of art for imaging for diagnosis of valvular disease and assessment of risk
    F Pinto / POR
  • Aortic valve disease
    A Abizaid / Brazil
  • Tricuspid disease
    H Sievert / GER
  • Mitral valve disease
    W Abraham / USA
Global challenges & opportunities for hf diagnosis, treatment, research
(U. OF LISBON, CHARITÉ, THE WORLD HEART FEDERATION)

Session 9 (8:30pm-10pm)

Difficult problems in HF

  • The patient with low blood pressure and poor renal function with acute HF
    S Matskeplishvili / RUS
  • Elderly patient with mid-range EF and suspicion of amyloid
    S Zieroth / CAN
  • Causes and management of heart failure in low resource settings – K Sliwa / SA
  • The patient with cancer and cardio-toxic chemotherapy
    A Lyon / UK
Looking to register a group of 10 or more? contact: “[email protected]”.

Thank You!